{"created":"2023-07-27T06:56:21.393711+00:00","id":53194,"links":{},"metadata":{"_buckets":{"deposit":"b4adb6fa-fb15-4699-9fff-317b5cec02d7"},"_deposit":{"created_by":18,"id":"53194","owners":[18],"pid":{"revision_id":0,"type":"depid","value":"53194"},"status":"published"},"_oai":{"id":"oai:kanazawa-u.repo.nii.ac.jp:00053194","sets":["2812:2813:2820"]},"author_link":["95222","47761"],"item_9_biblio_info_8":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2014-05-27","bibliographicIssueDateType":"Issued"},"bibliographicPageStart":"4p.","bibliographicVolumeNumber":"2011 – 2013","bibliographic_titles":[{"bibliographic_title":"平成25(2013)年度 科学研究費補助金 基盤研究(C) 研究成果報告書"},{"bibliographic_title":"2013 Fiscal Year Final Research Report","bibliographic_titleLang":"en"}]}]},"item_9_creator_33":{"attribute_name":"著者別表示","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{}],"nameIdentifiers":[{},{}]}]},"item_9_description_21":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"GSK3betaは糖代謝や細胞の増殖，分化，接着，運動などに関与する多機能酵素である。現在、開発が進められているGSK3beta阻害剤は治療薬に至っていない。GSK3beta阻害剤のがん治療への早期応用には日常診療で処方されている既存医薬品をがん治療に転用できるのではないかという着想から、GSK3beta阻害効果が判明した既存医薬品について、消化器がんを対象にがん抑制効果を検討した。医薬品は単剤使用で抗腫瘍活性を示し、併用使用でより効果的であった。以上の結果は、既存医薬品をDrug Repositioningとして利用した安全性の高い消化器がん治療臨床試験開始の足がかりになることを示唆した。","subitem_description_type":"Abstract"},{"subitem_description":"GSK3beta is a serine/threonine protein kinase that implicated in diseases including cancer. To date, there are no clinical trial reports describing the use of specific GSK3beta inhibitors for cancer, while our results of basic research have identified GSK3beta as a tumor promoter and druggable target for cancer treatment. Several drugs prescribed for diseases other than cancer were shown to have an inhibitory effect against GSK3beta. Here we show that inhibition of GSK3beta by using these drugs, alone or in combination, compromises survival, proliferation, migration and invasion of human colon and pancreatic cancer cells. We also show that the combination of GSK3beta-inhibiting drugs is more effective than the single agent treatment against both types of cancer cell lines. Our findings warrant further investigation and preclinical study on the effective combination of GSK3beta-inhibiting drugs and that with chemotherapeutic agents for treatment of gastrointestinal cancer.","subitem_description_type":"Abstract"}]},"item_9_description_22":{"attribute_name":"内容記述","attribute_value_mlt":[{"subitem_description":"研究課題/領域番号:23591955, 研究期間(年度):2011 – 2013","subitem_description_type":"Other"},{"subitem_description":"出典：「GSK3β阻害による消化器がん治療法の開発と分子機構の解明」研究成果報告書　課題番号23591955\n（KAKEN：科学研究費助成事業データベース（国立情報学研究所）） \n（https://kaken.nii.ac.jp/ja/report/KAKENHI-PROJECT-23591955/23591955seika/）を加工して作成","subitem_description_type":"Other"}]},"item_9_description_5":{"attribute_name":"提供者所属","attribute_value_mlt":[{"subitem_description":"金沢大学がん進展制御研究所","subitem_description_type":"Other"}]},"item_9_identifier_registration":{"attribute_name":"ID登録","attribute_value_mlt":[{"subitem_identifier_reg_text":"10.24517/00059479","subitem_identifier_reg_type":"JaLC"}]},"item_9_relation_28":{"attribute_name":"関連URI","attribute_value_mlt":[{"subitem_relation_name":[{"subitem_relation_name_text":"https://kaken.nii.ac.jp/ja/search/?kw=00353524"}],"subitem_relation_type_id":{"subitem_relation_type_id_text":"https://kaken.nii.ac.jp/ja/search/?kw=00353524","subitem_relation_type_select":"URI"}},{"subitem_relation_name":[{"subitem_relation_name_text":"https://kaken.nii.ac.jp/ja/grant/KAKENHI-PROJECT-23591955/"}],"subitem_relation_type_id":{"subitem_relation_type_id_text":"https://kaken.nii.ac.jp/ja/grant/KAKENHI-PROJECT-23591955/","subitem_relation_type_select":"URI"}},{"subitem_relation_name":[{"subitem_relation_name_text":"https://kaken.nii.ac.jp/ja/report/KAKENHI-PROJECT-23591955/23591955seika/"}],"subitem_relation_type_id":{"subitem_relation_type_id_text":"https://kaken.nii.ac.jp/ja/report/KAKENHI-PROJECT-23591955/23591955seika/","subitem_relation_type_select":"URI"}}]},"item_9_version_type_25":{"attribute_name":"著者版フラグ","attribute_value_mlt":[{"subitem_version_resource":"http://purl.org/coar/version/c_ab4af688f83e57aa","subitem_version_type":"AM"}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2020-11-05"}],"displaytype":"detail","filename":"CA-PR-HIROSE-M-kaken 2014-4p.pdf","filesize":[{"value":"163.7 kB"}],"format":"application/pdf","licensetype":"license_11","mimetype":"application/pdf","url":{"label":"CA-PR-HIROSE-M-kaken 2014-4p.pdf","url":"https://kanazawa-u.repo.nii.ac.jp/record/53194/files/CA-PR-HIROSE-M-kaken 2014-4p.pdf"},"version_id":"08ca4945-5001-4af4-9967-5d68b5705c18"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"jpn"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"research report","resourceuri":"http://purl.org/coar/resource_type/c_18ws"}]},"item_title":"GSK3β阻害による消化器がん治療法の開発と分子機構の解明","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"GSK3β阻害による消化器がん治療法の開発と分子機構の解明"},{"subitem_title":"Therapeutic effect of the GSK3beta-inhibiting drugs against gastrointestinal cancer and the elucidation of a molecular mechanism","subitem_title_language":"en"}]},"item_type_id":"9","owner":"18","path":["2820"],"pubdate":{"attribute_name":"公開日","attribute_value":"2020-11-05"},"publish_date":"2020-11-05","publish_status":"0","recid":"53194","relation_version_is_last":true,"title":["GSK3β阻害による消化器がん治療法の開発と分子機構の解明"],"weko_creator_id":"18","weko_shared_id":-1},"updated":"2023-07-27T09:15:30.723519+00:00"}